Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-Analysis of the Literature

Therapies Monday, October 22nd, 2012

American Heart Association, Inc.: October 15, 2012

Novel oral anticoagulants (NOACs) have been proposed as alternatives to vitamin K antagonists (VKAs) for prevention of stroke and systemic embolism (SE) in patients with atrial fibrillation (AF). Individually, NOACs were at least non-inferior to VKAs, but a clear superiority in overall and vascular mortality was not consistently proven.

Methods and Results—We performed a meta-analysis of phase-II and phase-III randomized controlled trials comparing NOACs with VKAs in patients with AF. MEDLINE and EMBASE databases, supplemented with conferences abstract books and www.clinicaltrial.gov, were searched up to July 2012 week 1, without any language restriction. Two reviewers performed independent article review and study quality assessment.  Read more

National Minority Quality Forum Clinical Trial Engagement Network Map Childhood Obesity MapHIV Z-Atlas: Peripheral Arterial Disease Atlas Map Lung Cancer Index Z-Atlas: Chronic Kidney Disease AFIB Index Cardiometabolic Health Aliance Minority Diabetes Coalition U.S. Diabetes Index County Edition U.S. Diabetes Index Research Edition Medicare Index Medicare Index Stroke Edition About The Minority Stroke Working Group Hepatitis C Disease Index Lead Risk Index Map MRSA StrokePAD Minority Index The South Texas Diabetes Initiative Minority Stroke Consortium YouTube NMQF Videos IPAB Action Center National Health Index

© 2011 National Minority Quality Forum, Inc. All Rights Reserved.